[go: up one dir, main page]

CY1107750T1 - Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης - Google Patents

Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης

Info

Publication number
CY1107750T1
CY1107750T1 CY20071101262T CY071101262T CY1107750T1 CY 1107750 T1 CY1107750 T1 CY 1107750T1 CY 20071101262 T CY20071101262 T CY 20071101262T CY 071101262 T CY071101262 T CY 071101262T CY 1107750 T1 CY1107750 T1 CY 1107750T1
Authority
CY
Cyprus
Prior art keywords
release
controlled
ssri
formulation
polymosphatic
Prior art date
Application number
CY20071101262T
Other languages
English (en)
Inventor
Theresa Ann Jeary
Catherine Ann Morrissey
Paul Stark
Original Assignee
Elan Pharma International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IE19990406A external-priority patent/IE990406A1/en
Application filed by Elan Pharma International Limited filed Critical Elan Pharma International Limited
Publication of CY1107750T1 publication Critical patent/CY1107750T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Ένα πολυσωματιδιακό σκεύασμα ελεγχόμενης αποδέσμευσης εκλεκτικού αναστολέα επαναπρόσληψης σεροτονίνης (SSRI) για στοματική χορήγηση περιλαμβάνει σωματίδια του εν λόγω SSRI ή ενός φαρμακευτικώς αποδεκτού άλατος αυτού επικαλυμμένα με πολυμερές ελέγχου της ταχύτητας το οποίο καθιστά δυνατή την ελεγχόμενη αποδέσμευση του εν λόγω SSRI, μέσα σε μια περίοδο όχι μικρότερη από περίπου 12 ώρες μετά την στοματική χορήγηση. Το σκεύασμα, το οποίο περιέχει για παράδειγμα φλουβοξαμίνη ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, είναι κατάλληλο για καθημερινή χορήγηση μία φορά ή δύο φορές. Το σκεύασμα μπορεί να περιλαμβάνει ένα μείγμα δύο ή περισσότερων πληθυσμών σωματιδίων, πελετών ή μικρο-δισκίων που έχουν διαφορετικά in vitro και/ή in vivo χαρακτηριστικά αποδέσμευσης.
CY20071101262T 1999-05-20 2007-10-04 Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης CY1107750T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13502899P 1999-05-20 1999-05-20
IE19990406A IE990406A1 (en) 1999-05-20 1999-05-20 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP00925548A EP1178780B1 (en) 1999-05-20 2000-05-10 Multiparticulate controlled release selective serotonin reuptake inhibitor formulations

Publications (1)

Publication Number Publication Date
CY1107750T1 true CY1107750T1 (el) 2013-04-18

Family

ID=26320248

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101262T CY1107750T1 (el) 1999-05-20 2007-10-04 Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης

Country Status (16)

Country Link
EP (2) EP1178780B1 (el)
JP (1) JP2003500348A (el)
AT (1) ATE367153T1 (el)
AU (1) AU782059B2 (el)
CA (2) CA2374039C (el)
CY (1) CY1107750T1 (el)
CZ (1) CZ302388B6 (el)
DE (1) DE60035579T2 (el)
DK (1) DK1178780T3 (el)
DZ (1) DZ3256A1 (el)
ES (1) ES2290027T3 (el)
HU (1) HU229569B1 (el)
PT (1) PT1178780E (el)
RU (1) RU2275191C2 (el)
SK (1) SK286865B6 (el)
WO (1) WO2000071099A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
BR0100334A (pt) * 2001-01-17 2002-09-24 Diffucap Chemobras Quimica E F Processo para a preparação de composições de liberação programada contendo venlafaxina e o produto resultante
ATE321544T1 (de) * 2001-11-07 2006-04-15 Synthon Bv Tamsulosin tabletten
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
EP1502587B1 (en) 2003-07-30 2006-08-23 Pharmathen S.A. Sustained release formulation for Venlafaxine hydrochloride
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
CA2476101A1 (en) * 2004-08-12 2006-02-12 Bernard Charles Sherman Extended-release capsules comprising venlafaxine hydrochloride
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
JP2008231025A (ja) * 2007-03-20 2008-10-02 Kyowa Yakuhin Kogyo Kk マレイン酸フルボキサミン錠剤
WO2018206923A1 (en) * 2017-05-11 2018-11-15 Opal Ip Limited Novel formulations
WO2025111679A1 (pt) * 2023-11-30 2025-06-05 Prati, Donaduzzi & Cia Ltda Forma farmacêutica oral para liberação bifásica, composta por um sistema multiparticulado, processo para preparação da mesma e uso terapêutico da forma oral

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE124864T1 (de) * 1989-03-10 1995-07-15 Yamanouchi Pharma Co Ltd Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
JPH04234812A (ja) * 1990-03-16 1992-08-24 Yamanouchi Pharmaceut Co Ltd 持続性製剤用顆粒
JPH0826977A (ja) * 1994-07-19 1996-01-30 Tanabe Seiyaku Co Ltd 溶出制御型経口製剤
JP4072597B2 (ja) * 1994-12-27 2008-04-09 ナムローゼ・フェンノートシャップ・オルガノン 持続性製剤
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
EA001906B1 (ru) * 1997-07-01 2001-10-22 Пфайзер Продактс Инк. Лекарственные формы с замедленным высвобождением сертралина
CN1256085C (zh) * 1997-07-01 2006-05-17 美国辉瑞有限公司 舍曲林盐和舍曲林的缓释剂型
UA77145C2 (en) * 1997-11-05 2006-11-15 Wyeth Corp Extended release dosage formulation

Also Published As

Publication number Publication date
CZ302388B6 (cs) 2011-04-27
AU4426700A (en) 2000-12-12
DE60035579D1 (de) 2007-08-30
CA2374039C (en) 2011-01-11
HUP0201884A3 (en) 2006-07-28
EP1178780A1 (en) 2002-02-13
EP1178780B1 (en) 2007-07-18
WO2000071099A1 (en) 2000-11-30
HU229569B1 (hu) 2014-02-28
ES2290027T3 (es) 2008-02-16
AU782059B2 (en) 2005-06-30
EP1852111A1 (en) 2007-11-07
CZ20014618A3 (cs) 2002-05-15
CA2374039A1 (en) 2000-11-30
HUP0201884A2 (en) 2002-09-28
CA2698347A1 (en) 2000-11-30
ATE367153T1 (de) 2007-08-15
DZ3256A1 (fr) 2000-11-30
SK286865B6 (sk) 2009-06-05
DE60035579T2 (de) 2008-04-17
PT1178780E (pt) 2007-10-25
JP2003500348A (ja) 2003-01-07
RU2275191C2 (ru) 2006-04-27
SK18962001A3 (sk) 2002-04-04
DK1178780T3 (da) 2007-11-12

Similar Documents

Publication Publication Date Title
CY1107750T1 (el) Πολυσωματιδιακα σκευασματα ελεγχομενης αποδεσμευσης εκλεκτικου αναστολεα επαναπροσληψης σεροτονινης
AR027059A1 (es) Bases de mannich indolicas, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su uso para la preparacion de medicamentos
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
HRP20010514B1 (en) Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament
ES2084944T3 (es) Amidas terapeuticas.
PE20030527A1 (es) Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
ES2161418T3 (es) Compuestos de piridilfurano y de piridiltiofeno y uso farmaceutico de los mismos.
CY1107729T1 (el) Φαρμακευτικες συνθεσεις
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
AR021934A1 (es) Composicion de administracion oral con liberacion controlada de al menos un analgesico
FI895520A0 (fi) Anti-aterosklerotiska diaryl foereningar.
EA200300110A1 (ru) Композиция элетриптана в виде частиц
YU36401A (sh) Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem
CA2415154A1 (en) Modified release formulations of selective serotonin re-uptake inhibitors
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
IT9019793A0 (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ATE81775T1 (de) Pharmazeutische zusammensetzungen.
UA74335C2 (uk) Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну
AR028823A1 (es) 8a y 9a lactamas de 15 miembros de la clase 6-o-metil-eritromicina a, un procedimiento para su preparacion y una composicion farmaceutica util para el tratamiento de infecciones bacterianas en seres humanos y animales
ES2084585T3 (es) Derivados de la 6-oxo-piridazina, procedimiento para su obtencion y medicamentos que contienen estos compuestos.
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB